Most evaluable subjects had TP53 wild type (wt), while 9% (N = 7) had del(17p) or mutated TP53. Unmutated IGHV was observed in 48% of evaluable patients (N = 37), and 4 of them (5.2%) had also mutated TP53; conversely, 40 subjects had mutated IGHV, and 3 of them (4%) displayed mutated TP53. The most frequent comorbidity was hypertension (44%; N = 101), followed by dyslipidemia (15%; N = 35), diabetes (13%; N = 29), ischemic cardiomyopathy (11%; N =25), benign prostatic hyperplasia (11%; N = 25), chronic obstructive pulmonary disease (COPD; 10%; N = 24), and atrial fibrillation (9%; N = 20). This evidence concerns the gene TP53 and chronic obstructive pulmonary disease.